A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
Live Science on MSN4h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...
Telehealth platforms like Motivated are changing how men treat ED with its fast, affordable, and discreet online service.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback